Last reviewed · How we verify
JP-2266
At a glance
| Generic name | JP-2266 |
|---|---|
| Sponsor | Jeil Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients (PHASE2)
- Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Characteristics of JP-2266 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JP-2266 CI brief — competitive landscape report
- JP-2266 updates RSS · CI watch RSS
- Jeil Pharmaceutical Co., Ltd. portfolio CI